To include your compound in the COVID-19 Resource Center, submit it here.

Supercharging Astex

SuperGen-Astex merger aims to create mid-tier cancer company

SuperGen Inc. and Astex Therapeutics Ltd. are betting that by combining the former's cash with the latter's pipeline and drug discovery platform, they can create a mid-tier cancer company.

SuperGen has plenty of cash from Dacogen decitabine royalties and needs a cancer pipeline to fill the gap if Dacogen cannot add new indications that will extend its Orphan exclusivity.

Astex has a cancer pipeline and a discovery engine but needs cash for clinical development.

The combined company will start out with about $120 million in the bank, partnerships with five big pharmas, royalties from one marketed drug, seven NCEs in clinical development, and a preclinical pipeline that should produce a new IND every 12-18 months for about eight years, according to SuperGen Chairman, President and CEO James Manuso.

Changing models

For SuperGen, the merger is a logical step in achieving its third incarnation, as a drug discovery company.

The company was founded in 1991 to develop cyclodextrin-coated chemotherapies to create timed-release "super generics." But after clinical data showed the products were not sufficiently differentiated, SuperGen moved to a specialty pharma model with two key product acquisitions in the late 1990s.

In 1996, the company acquired hairy cell leukemia drug Nipent pentostatin for undisclosed cash and equity

Read the full 1998 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE